Up­dat­ed: Ag­i­lent throws down $725M to dou­ble man­u­fac­tur­ing ca­pac­i­ty for nu­cle­ic acids to meet API de­mand

A life sci­ence CD­MO is in­vest­ing hun­dreds of mil­lions of dol­lars in­to man­u­fac­tur­ing nu­cle­ic acids amid in­creas­ing de­mand for ac­tive phar­ma­ceu­ti­cal in­gre­di­ents, or API. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER